LEGN · Company research

Legend Biotech Corporation

2 upcoming catalysts · 0 phase 2+ trials on file

View Stock opens Yahoo Finance. Prices and performance charts are provided there.

Upcoming catalysts

MilestoneLEGNLegend BiotechH2 2026

Legend targets multiple IND filings (oncology, autoimmune) starting 2H 2026, expected in the second half of 2026 (no exact date yet). A company milestone for Legend Biotech (in vivo CAR-T / pipeline for oncology and autoimmune): a step in the program rather than a decision or a data readout.

More details

Entry

Legend targets multiple IND filings (oncology, autoimmune) starting 2H 2026 · Company milestone

Drug

in vivo CAR-T / pipeline

For

oncology and autoimmune

Stage

IND

When

H2 2026 · the company gave a window, not a day

Source note

From Legend's JPM 2026 business update (Jan 12, 2026, via StockTitan mirror of company PR). The Aug 11, 2026 Q2 PR gave no dated forward milestones; LB2501 in vivo CAR-T PoC already reported at EHA 2026.

Checked

Checked by a person when it was added

Verify it

Source: stocktitan.net ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
LEGN headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsLEGNLegend Biotech2027

Legend Biotech expects to report results from its Phase 3 study of Carvykti (ciltacabtagene autoleucel) for Newly diagnosed multiple myeloma (transplant-ineligible: CARTITUDE-5; transplant-eligible: CARTITUDE-6) during 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details

Entry

CARTITUDE-5 and CARTITUDE-6 event-driven Phase 3 readouts: Carvykti in frontline multiple myeloma · Clinical trial results (readout / topline data)

Drug

Carvykti (ciltacabtagene autoleucel)

For

Newly diagnosed multiple myeloma (transplant-ineligible: CARTITUDE-5; transplant-eligible: CARTITUDE-6)

Stage

Phase 3 · the last stage before a drug can be approved

When

2027 · the company gave a window, not a day

Source note

Both J&J-partnered trials are fully enrolled but event-driven; management frames readouts as possible in 2026-2027 with no committed date. Dated 2027 as the midpoint of the guided window - treat as a floating catalyst.

Checked

Checked by a person when it was added

Verify it

Source: tipranks.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
LEGN headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Past catalysts

ConferenceLEGNLegend BiotechJun 14, 2026

Legend Biotech presented data on LB2501 for Relapsed/refractory B-cell non-Hodgkin lymphoma at a medical meeting on Jun 14, 2026. The linked source has the details.

More details

Entry

EHA 2026 late-breaker: LB2501 establishes in vivo CAR-T proof-of-concept · Data presented at a medical meeting

Drug

LB2501

For

Relapsed/refractory B-cell non-Hodgkin lymphoma

Stage

Phase 1 · an early safety study in a small group of people

When

Jun 14, 2026

Source note

Full LB2501 Phase 1 data were presented in an EHA 2026 late-breaking session (Abstract LB5006), showing dose-dependent in vivo CAR-T expansion without lymphodepletion, Grade 1-2 CRS only, plus translational data on rapid vector clearance and polyclonal integration.

Checked

Checked by a person when it was added

Verify it

Source: investors.legendbiotech.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
LEGN headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsLEGNLegend BiotechJun 2, 2026

Legend Biotech reported results from its Phase 1 study of LB2501 for Relapsed/refractory B-cell non-Hodgkin lymphoma on Jun 2, 2026. The study met its main goal.

More details

Entry

LB2501 in vivo CAR-T Phase 1: 100% ORR at dose level 2 in R/R B-NHL · Clinical trial results (readout / topline data)

Drug

LB2501

For

Relapsed/refractory B-cell non-Hodgkin lymphoma

Stage

Phase 1 · an early safety study in a small group of people

When

Jun 2, 2026

Source note

Ahead of an EHA late-breaking session, Legend disclosed preliminary Phase 1 data for in vivo CD19/CD20 CAR-T LB2501 showing 100% ORR (6/6) and 83.3% CR at dose level 2 without lymphodepleting chemotherapy, with no DLTs, SAEs or ICANS.

Checked

Checked by a person when it was added

Verify it

Source: investors.legendbiotech.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
LEGN headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

ConferenceLEGNLegend BiotechJun 1, 2026

Legend Biotech presented data on LB2102 (DLL3 CAR-T); CARVYKTI (cilta-cel) for Small cell lung cancer / LCNEC; multiple myeloma at a medical meeting on Jun 1, 2026. The linked source has the details.

More details

Entry

ASCO 2026: LB2102 first-in-human ORR 28.6% in SCLC; new CARVYKTI data · Data presented at a medical meeting

Drug

LB2102 (DLL3 CAR-T); CARVYKTI (cilta-cel)

For

Small cell lung cancer / LCNEC; multiple myeloma

Stage

Phase 1 · an early safety study in a small group of people

When

Jun 1, 2026

Source note

Legend reported first-in-human results for DLL3-targeted CAR-T LB2102 in relapsed/refractory small cell lung cancer and LCNEC, with a 28.6% ORR and 78.6% disease control rate at higher dose levels. New CARTITUDE analyses reinforcing CARVYKTI durability were also presented.

Checked

Checked by a person when it was added

Verify it

Source: investors.legendbiotech.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
LEGN headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Things of Interest

Explore reported politician transactions and public investor statements connected to LEGN.

View source-linked activity ↗

Pipeline trials

ClinicalTrials.gov · phase 2 and later

No phase 2+ trials cached for this company.

Company news

No recent headlines on file.